A policy approach to the development of molecular diagnostic tests.

Journal Article

Efficiently generating evidence of clinical utility is a major challenge for ensuring clinical adoption of valuable diagnostics. A new approach to reimbursement in the United States offers a balance between evidence and incentives for molecular diagnostic tests.

Full Text

Cited Authors

  • Schulman, KA; Tunis, SR

Published Date

  • November 2010

Published In

Volume / Issue

  • 28 / 11

Start / End Page

  • 1157 - 1159

PubMed ID

  • 21057480

Electronic International Standard Serial Number (EISSN)

  • 1546-1696

Digital Object Identifier (DOI)

  • 10.1038/nbt1110-1157


  • eng

Conference Location

  • United States